Skip to main content

Bain Capital Life Sciences Fund, L.P.'s Form 4 filing

Rapid Micro Biosystems, Inc.RPID · filed May 22, 2026

Accession no.
0001193125-26-237016
Filed
May 22, 2026, 4:30 PM ET
Trade date
May 20, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 derivative transactions. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bain Capital Life Sciences Fund, L.P.CIK 000168796810% Owner
BCIP Life Sciences Associates, LPCIK 000170292110% Owner
Bain Capital Life Sciences Partners, LPCIK 000170303010% Owner
Bain Capital Life Sciences Investors, LLCCIK 000170303110% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 20, 2026Class A Common StockPPurchaseAcquired+1,463,000–F1–1,463,000Indirect
May 20, 2026Class A Common StockPPurchaseAcquired+1,463,000–F1–1,463,000Indirect
May 20, 2026Class A Common StockPPurchaseAcquired+1,463,000–F1–1,463,000Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

Referenced by the price of 3 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)